Asset
Indication
Preclinical
Phase I
Phase 2A
Phase 2B
Phase 3
Status
Resomelagon
(AP1189)
Rheumatoid arthritis (RA)
- 1st line treatment together Methotrexate
• ADVANCE – Phase 2b study – recruitment completed
Host-Directed Therapy in Viral Infections (Dengue virus)
• RESOVIR-2 – Phase 2a – Proof of Concept study PoC in Arboviral infection (Dengue fever) – ongoing
Idiopathic Membranous
Nephropathy (iMN)
• START – Phase 2a study – ongoing
TXP-11
Prevent organ
failure in surgery
• Preclinical pharmacology to support Phase 1 CTA ongoing – Aim to be Ph 1 ready in 2026
Next generation
molecules
Autoimmune &
inflammatory diseases
• Discovery
Polymyalgia Rheumatica (PMR)
• Phase 2a study – ongoing (rare disease potential)
Host-Directed Therapy in Viral Infections (Respiratory infections)
• RESPIRE – Phase 2 – Hyperinflammation due to respiratory infections (Influenza, Covid-19, RSV) – ongoing
Completed Ongoing